


***BCR::ABL1* Qualitative Diagnostic Assay with Reflex to *BCR::ABL1* p190 Quantitative Assay or *BCR::ABL1* p210 Quantitative Assay, Varies**

Test ID: BCRFX

Explanation: The Testing Algorithm and Ordering Guidance will be updated on the effective date to include the newly available monitoring test, BARQ.

<p>Current Testing Algorithm</p> <p>When a positive common p210 or p190 <i>BCR::ABL1</i> result is identified by the qualitative assay, a reflex test will then be performed at an additional charge to determine the quantitative transcript level of <i>BCR::ABL1</i> messenger RNA. A positive common p210 or p190 result will specifically trigger either quantitative p210 or p190 testing to provide a normalized percentage of transcript level. For the p210 target, the value is additionally defined using the international scale convention. The results are released in an integrated report and provide a baseline quantitative transcript to monitor treatment response. If the initial qualitative testing is negative, or an alternate rare form of <i>BCR::ABL1</i> is detected, then no reflex testing will be pursued, and the initial results will be reported.</p> <p>For more information see: -Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation -Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation</p>	<p>New Testing Algorithm</p> <p>If the initial qualitative testing is negative, no additional testing will be performed.</p> <p>If the initial qualitative testing is positive for the common p190 or p210 <i>BCR::ABL1</i> forms, reflex testing to determine the quantitative transcript level of the relevant messenger RNA will be performed at an additional charge. A normalized percentage of transcript level is provided in an integrated report. For the p210 target, the value is additionally defined using the international scale convention. These integrated results provide a baseline quantitative transcript to monitor treatment response.</p> <p>If the initial qualitative testing is positive for an alternate rare form of <i>BCR::ABL1</i>, then BARQ / <i>BCR::ABL1</i> Rare Fusion Monitoring, Quantitative, Varies will be added and performed at an additional charge, with results reported separately.</p> <p>For more information see: -Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation -Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation -BCR/ABL1 Ordering Guide for Blood and Bone Marrow</p>
<p>Current Ordering Guidance</p> <p>Additional testing options are available. For ordering guidance see BCR/ABL1 Ordering Guide for Blood and Bone Marrow.</p>	<p>Updated Ordering Guidance</p> <p>This test should not be used to monitor <i>BCR::ABL1</i> fusion forms.</p> <p>To monitor patients carrying <i>BCR::ABL1</i> fusion forms coding for the p190 (e1/a2) protein, order BA190 / <i>BCR::ABL1</i>, p190, mRNA Detection, Reverse</p>



Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies.

To monitor patients carrying *BCR::ABL1* fusion forms coding for the p210 (e13/a2 or e14/a2) protein, order BCRAB / *BCR::ABL1*, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myeloid Leukemia (CML), Varies.

To monitor patients carrying rare *BCR::ABL1* fusion forms coding for e19a2, e13/e14a3, e1a3, e6a2, e19a3, e8a2, e12a2, e6a3, e8a3, and e12a3, order BARQ / *BCR::ABL1*, Rare Fusion Monitoring, Quantitative, Varies.

If the patient has a previous positive history of p190, p210, or rare fusion forms, this test will be cancelled and one of the following appropriate monitoring tests will be added:
-BA190 / *BCR::ABL1*, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies
-BCRAB / *BCR::ABL1*, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myeloid Leukemia (CML), Varies
-BARQ / *BCR::ABL1*, Rare Fusion Monitoring, Quantitative, Varies

If the specimen is greater than 72 hours post-collection when received, this test will be canceled and BADX / *BCR::ABL1*, Qualitative, Diagnostic Assay, Varies will be added and performed as the appropriate test if the specimen is still within stability for that test.

Questions

Contact Melissa Lonzo, Laboratory Resource Coordinator at 800-533-1710.